Pfizer hiked its projections for COVID vaccine revenues, telling investors this week it expects booster shots, a vaccine targeting the Delta variant and anticipated authorization of its vaccines for children as young as 6 months will drive revenues higher.
Aggregated data for fiscal year 2020 show the NIH and CDC collected a combined $63.4 million in royalty revenues under a business model that allows the NIH to grant technology licenses to the private sector.
Within six days of receiving a second injection of Pfizer’s experimental Wuhan coronavirus (Covid-19) vaccine, a two-year-old baby enrolled in the company’s clinical trials for children passed away, new reports indicate.